Scancell Holdings (SCP0) AI Stock Analysis

Scancell Holdings

(Frankfurt:SCP0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical and regulatory progressFDA clearance of the registrational Phase III design materially reduces regulatory uncertainty and establishes a defined development route. Acceptance of a surrogate endpoint could shorten the path to approval if efficacy is confirmed, strengthening the commercial potential of iSCIB1+.

Negative Factors

Persistent losses and cash burnPersistent operating and free cash outflows show that the business is not yet self-funding and must rely on external capital or partner receipts. Continued burn can constrain development choices and make execution more sensitive to financing availability over the next several quarters.

Scancell Holdings (SCP0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 105.95M
Dividend Yield: ―
Average Volume (3M): 793
Price to Earnings (P/E): -5.0
Beta (1Y): -2.00
Revenue Growth: -100.00%
EPS Growth: -26.96%
Country: Germany
Employees: 60
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The c...

Scancell Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:SCP0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:4BB	52Neutral	GBP 82.07M	-4.57	-316.73%	―	-56.10%	-16.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:AREC	49Neutral	GBP 37.37M	165.00	3.75%	―	―	―
GB:SAR	47Neutral	GBP 24.95M	-4.19	-284.01%	―	―	-105.65%
GB:POLB	46Neutral	GBP 49.62M	-8.33	-71.28%	―	―	31.58%
GB:OBI	44Neutral	GBP 64.47M	-2.83	-9999.00%	―	26.99%	4.36%

* Healthcare Sector Average

Performance Comparison

DE:SCP0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:SCP0	Scancell Holdings	1.02	0.25	31.95%
GB:SAR	Sareum Holdings	15.25	0.75	5.17%
GB:4BB	4basebio UK Societas	530.00	-255.00	-32.48%
GB:POLB	Poolbeg Pharma Ltd.	6.50	2.65	68.83%
GB:AREC	Arecor Therapeutics PLC	82.50	11.00	15.38%
GB:OBI	Ondine Biomedical, Inc.	9.75	-3.00	-23.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Scancell Holdings AI Stock Analysis